Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
21.76
-0.37 (-1.67%)
Aug 1, 2025, 4:00 PM - Market closed
Tourmaline Bio Stock Forecast
Stock Price Forecast
The 6 analysts that cover Tourmaline Bio stock have a consensus rating of "Strong Buy" and an average price target of $49.33, which forecasts a 126.70% increase in the stock price over the next year. The lowest target is $25 and the highest is $70.
Price Target: $49.33 (+126.70%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 5, 2025.
Analyst Ratings
The average analyst rating for Tourmaline Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +129.78% | May 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $70 | Strong Buy | Maintains | $70 | +221.69% | May 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +221.69% | Apr 23, 2025 |
| Wedbush | Wedbush | Buy Maintains $42 → $43 | Buy | Maintains | $42 → $43 | +97.61% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $50 | Strong Buy | Maintains | $49 → $50 | +129.78% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
6.12M
Revenue Next Year
6.12M
from 6.12M
EPS This Year
-3.64
from -2.89
EPS Next Year
-4.30
from -3.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.0M | 63.0M | 63.0M | ||
| Avg | 6.1M | 6.1M | 14.0M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 929.4% | 929.4% | ||
| Avg | - | - | 129.2% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.89 | -3.06 | -3.21 | ||
| Avg | -3.64 | -4.30 | -5.15 | ||
| Low | -4.19 | -5.42 | -9.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.